Vertex Pharmaceuticals Expands Portfolio with Acquisition of Alpine Immune Sciences

Wednesday, 10 April 2024, 21:15

In a significant move, Vertex Pharmaceuticals has announced its acquisition of Alpine Immune Sciences for a sizable $4.9 billion. This strategic deal is aimed at enhancing Vertex's presence in the field of kidney diseases amidst a growing trend of biotechnology acquisitions. The acquisition signals Vertex's commitment to expanding its portfolio and staying competitive in the evolving healthcare landscape.

LivaRava Finance Meta Image — Vertex Pharmaceuticals Expands Portfolio with Acquisition of Alpine Immune Sciences

Vertex Pharmaceuticals Acquires Alpine Immune Sciences for $4.9 Billion

Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue to heat up.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.